+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product, Disease Indication, End Use, Region, and Segment Forecasts, 2026-2033- Product Image
CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product, Disease Indication, End Use, Region, and Segment Forecasts, 2026-2033- Product Image
New

CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product, Disease Indication, End Use, Region, and Segment Forecasts, 2026-2033

  • PDF Icon

    Report

  • 150 Pages
  • February 2026
  • Region: Global
  • Grand View Research
  • ID: 5846829
REQUEST CUSTOMIZATION
Description Jump to:
The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, growing at a CAGR of 18.06% from 2026 to 2033. Market growth is driven by rising cancer prevalence, adoption of personalized cell therapies, advances in gene editing, and supportive regulations.

Rising Cancer Burden

The rising prevalence of cancer, especially blood cancers like leukemia, lymphoma, and multiple myeloma, is driving the CAR T-cell therapy industry. Traditional treatments often fail to achieve long-term remission, while CAR T-cell therapies, which engineer a patient’s T-cells to target cancer, offer higher efficacy and durable responses. Increasing global cancer incidence is boosting demand for these advanced, personalized treatments.

Limited options for aggressive or treatment-resistant blood cancers support CAR T-cell market growth. These therapies address critical unmet needs, and rising awareness among healthcare professionals and patients is driving adoption. Expanding clinical trials into other cancers and solid tumors is expected to increase demand further, making CAR T-cell therapy a central focus in oncology.

Global CAR T-cell Therapy Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the global CAR T-cell therapy market report based on product, disease indication, end use, and region:

Product Outlook (Revenue, USD Million, 2021-2033)

  • Abecma (idecabtagene vicleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Carvykti (ciltacabtagene autoleucel)
  • Kymriah (tisagenlecleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Yescarta (axicabtagene ciloleucel)
  • Others

Disease Indication Outlook (Revenue, USD Million, 2021-2033)

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others

End Use Outlook (Revenue, USD Million, 2021-2033)

  • Hospitals
  • Cancer Treatment Centers

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia Pacific
  • Rest of World

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Disease Indication Segment
1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.4.1. Objective 1
1.4.2. Objective2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising cancer burden
3.2.1.2. Personalized treatment advantage
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory complexity
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Product Business Analysis
4.1. Product Segment Dashboard
4.2. CAR T-cell Therapy Market: Product Movement Analysis
4.3. Abecma (idecabtagene vicleucel)
4.3.1. Abecma (idecabtagene vicleucel) market, 2021-2033 (USD Million)
4.4. Breyanzi (lisocabtagene maraleucel)
4.4.1. Breyanzi (lisocabtagene maraleucel) market, 2021-2033 (USD Million)
4.5. Carvykti (ciltacabtagene autoleucel)
4.5.1. Carvykti (ciltacabtagene autoleucel) market, 2021-2033 (USD Million)
4.6. Kymriah (tisagenlecleucel)
4.6.1. Kymriah (tisagenlecleucel) market, 2021-2033 (USD Million)
4.7. Tecartus (brexucabtagene autoleucel)
4.7.1. Tecartus (brexucabtagene autoleucel) market, 2021-2033 (USD Million)
4.8. Yescarta (axicabtagene ciloleucel)
4.8.1. Yescarta (axicabtagene ciloleucel) market, 2021-2033 (USD Million)
4.9. Others
4.9.1. Others market, 2021-2033 (USD Million)
Chapter 5. Disease Indication Business Analysis
5.1. Disease Indication Segment Dashboard
5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
5.3. Leukemia
5.3.1. Leukemia market, 2021-2033 (USD Million)
5.4. Lymphoma
5.4.1. Lymphoma market, 2021-2033 (USD Million)
5.5. Multiple Myeloma
5.5.1. Multiple myeloma market, 2021-2033 (USD Million)
5.6. Others
5.6.1. Others market, 2021-2033 (USD Million)
Chapter 6. End Use Business Analysis
6.1. End Use Segment Dashboard
6.2. CAR T-cell Therapy Market: End Use Movement Analysis
6.3. Hospitals
6.3.1. Hospitals market, 2021-2033 (USD Million)
6.4. Cancer treatment centers
6.4.1. Cancer treatment centers market, 2021-2033 (USD Million)
Chapter 7. Regional Business Analysis
7.1. CAR T-cell Therapy Market Share By Region, 2025 & 2033
7.2. North America
7.2.1. North America CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.3. Europe
7.3.1. Europe CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China CAR T-cell Therapy Market, 2021-2033 (USD Million)
7.5. Rest of World
7.5.1. Rest of World CAR T-cell Therapy Market, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Position Analysis, 2025
8.4. Company Profiles/Listing
8.4.1. Bristol-Myers Squibb Company
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Gilead Sciences, Inc.
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Johnson & Johnson Services, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. bluebird bio, Inc.
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Merck & Co., Inc.
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Sangamo Therapeutics
8.4.8.1. Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Sorrento Therapeutics, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. GSK plc.
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
List of Tables
Table 1. Global CAR T-cell therapy market, by region, 2021-2033 (USD Million)
Table 2. Global CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 3. Global CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 4. Global CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 5. North America CAR T-cell therapy market, by country, 2021-2033 (USD Million)
Table 6. North America CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 7. North America CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 8. North America CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 9. U.S. CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 10. U.S. CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 11. U.S. CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 12. Canada CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 13. Canada CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 14. Canada CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 15. Europe CAR T-cell therapy market, by country, 2021-2033 (USD Million)
Table 16. Europe CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 17. Europe CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 18. Europe CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 19. UK CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 20. UK CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 21. UK CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 22. Germany CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 23. Germany CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 24. Germany CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 25. Asia Pacific CAR T-cell therapy market, by country, 2021-2033 (USD Million)
Table 26. Asia Pacific CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 27. Asia Pacific CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 28. Asia Pacific CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 29. Japan CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 30. Japan CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 31. Japan CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 32. China CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 33. China CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 34. China CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
Table 35. Rest or World CAR T-cell therapy market, by country, 2021-2033 (USD Million)
Table 36. Rest of World CAR T-cell therapy market, by product, 2021-2033 (USD Million)
Table 37. Rest of World CAR T-cell therapy market, by disease indication, 2021-2033 (USD Million)
Table 38. Rest of World CAR T-cell therapy market, by end use, 2021-2033 (USD Million)
List of Figures
Figure 1 CAR T-cell therapy market segmentation
Figure 2 Data analysis models
Figure 3 Market formulation and validation
Figure 4 Data validating & publishing
Figure 5 Market research process
Figure 6 Information procurement
Figure 7 Primary research
Figure 8 Value-chain-based sizing & forecasting
Figure 9 QFD modelling for market share assessment
Figure 10 Market formulation & validation
Figure 11 Commodity flow analysis
Figure 12 Market outlook
Figure 13 Segment snapshot
Figure 14 Competitive landscape snapshot
Figure 15 Market trends & outlook
Figure 16 PESTEL analysis
Figure 17 Porter’s five forces analysis
Figure 18 CAR T-cell therapy market: Product outlook & key takeaways
Figure 19 CAR T-cell therapy market: Product movement analysis
Figure 20 Global abecma (idecabtagene vicleucel) market, 2021-2033 (USD Million)
Figure 21 Global breyanzi (lisocabtagene maraleucel) market, 2021-2033 (USD Million)
Figure 22 Global carvykti (ciltacabtagene autoleucel) market, 2021-2033 (USD Million)
Figure 23 Global kymriah (tisagenlecleucel) market, 2021-2033 (USD Million)
Figure 24 Global tecartus (brexucabtagene autoleucel) market, 2021-2033 (USD Million)
Figure 25 Global yescarta (axicabtagene ciloleucel) market, 2021-2033 (USD Million)
Figure 26 Global others market, 2021-2033 (USD Million)
Figure 27 CAR T-cell therapy market: Disease Indication outlook key takeaways
Figure 28 CAR T-cell therapy market: Disease Indication movement analysis
Figure 29 Global leukemia market, 2021-2033 (USD Million)
Figure 30 Global lymphoma market, 2021-2033 (USD Million)
Figure 31 Global multiple myeloma market, 2021-2033 (USD Million)
Figure 32 Global others market, 2021-2033 (USD Million)
Figure 33 CAR T-cell therapy market: End Use outlook key takeaways
Figure 34 CAR T-cell therapy market: End Use movement analysis
Figure 35 Global hospitals market, 2021-2033 (USD Million)
Figure 36 Global cancer treatment centers market, 2021-2033 (USD Million)
Figure 37 Regional outlook
Figure 38 Regional marketplace: Key takeaways
Figure 39 North America CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 40 Key country dynamics
Figure 41 US CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 42 Key country dynamics
Figure 43 Canada CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 44 Europe CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 45 Key country dynamics
Figure 46 Germany CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 47 Key country dynamics
Figure 48 UK CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 49 Asia Pacific CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 50 Key country dynamics
Figure 51 Japan CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 52 Key country dynamics
Figure 53 China CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 54 Rest of World CAR T-cell therapy market estimates and forecasts, 2021-2033 (USD Million)

Companies Mentioned

The leading players profiled in this CAR T-cell Therapy market report include:
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics (Shanghai) Co., Ltd.
  • bluebird bio, Inc.
  • Merck & Co., Inc.
  • Sangamo Therapeutics
  • Sorrento Therapeutics, Inc.
  • GSK plc.

Table Information

Report AttributeDetails
No. of Pages150
PublishedFebruary 2026
Forecast Period2025 - 2033
Estimated Market Value ( USD ) in 2025 $ 5.82 Billion
Forecasted Market Value ( USD ) by 2033 $ 22.36 Billion
Compound Annual Growth Rate18.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033 - Product Image

CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033

  • Report
  • 180 Pages
  • Global
From
Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), Indication (Oncology, Infectious Diseases), and Region with Growth Forecasts, 2025-2033 - Product Image

Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), Indication (Oncology, Infectious Diseases), and Region with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - Product Image

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

  • Report
  • 598 Pages
  • Global
From
Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III), By Indication (Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases), By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III), By Indication (Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases), By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • Global
From
CAR T-Cell Therapy for Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

CAR T-Cell Therapy for Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.